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Abstract
Background: One of the most important causes of maternal mortality and severe morbidity worldwide is post
partum haemorrhage (PPH). Factors as substandard care are frequently reported in the international literature and
there are similar reports in the Netherlands. The incidence of PPH in the Dutch population is 5% containing 10.000
women a year. The introduction of an evidence-based guideline on PPH by the Dutch society of Obstetrics and
Gynaecology (NVOG) and the initiation of the MOET course (Managing Obstetrics Emergencies and Trauma) did
not lead to a reduction of PPH. This implies the possibility of an incomplete implementation of both the NVOG
guideline and MOET-instructions. Therefore, the aim of this study is to develop and test a tailored strategy to
implement both the NVOG guideline and MOET-instructions
Methods/Design: One step in the development procedure is to evaluate the implementation of the guideline and
MOET-instructions in the current care. Therefore measurement of the actual care will be performed in a
representative sample of 20 hospitals. This will be done by prospective observation of the third stage of labour of
320 women with a high risk of PPH using quality indicators extracted from the NVOG guideline and MOET
instructions. In the next step barriers and facilitators for guideline adherence will be analyzed by performance of
semi structured interviews with 30 professionals and 10 patients, followed by a questionnaire study among all
Dutch gynaecologists and midwives to quantify the barriers mentioned. Based on the outcomes, a tailored strategy
to implement the NVOG guideline and MOET-instructions will be developed and tested in a feasibility study in 4
hospitals, including effect-, process- and cost evaluation.
Discussion: This study will provide insight into current Dutch practice, in particular to what extent the PPH
guidelines of the NVOG and the MOET-instructions have been implemented in the actual care, and into the
barriers and facilitators regarding guideline adherence. The knowledge of the feasibility study regarding the effects
and costs of the tailored strategy and the experiences of the users can be used in countries with a relatively high
incidence of PPH.
Trial Registration: ClinicTrials.gov NCT00928863
* Correspondence: M.Woiski@obgyn.umcn.nl
† Contributed equally
1Department of Obstetrics and Gynaecology, Radboud University Nijmegen,
Nijmegen, the Netherlands
Woiski et al. BMC Pregnancy and Childbirth 2010, 10:5
http://www.biomedcentral.com/1471-2393/10/5
© 2010 Woiski et al; licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons
Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in
any medium, provided the original work is properly cited.
Background
The major cause of maternal death worldwide is post par-
tum haemorrhage (PPH, blood loss of >1000 cc during
and after delivery), with about 146.000 deaths annually [1].
Although this is largely due to deaths in developing coun-
tries, even in the Netherlands it is still in the top four of
maternal deaths [2]. In this country the reported incidence
of PPH is 5% in the secondary care, affecting about 10.000
women annually [3]. In the Lemmon trial (2004-2006), in
which a large part of Dutch hospitals participated, all
severe maternal morbidity was documented and PPH in
absolute number is the major factor contributing to severe
maternal morbidity [4]. Causes such as substandard care
are frequently reported in the international literature. In a
study in France, suboptimal care factors were found in
38% of women with PPH > 1500 cc and in 70% of women
who died of PPH. In audits, performed in PPH cases of
the Lemmon trial, suboptimal care factors were also com-
mon in the Dutch population (unpublished data). A logical
assumption is that these factors can be overcome by the
use of evidence based guidelines. The Dutch Society of
Obstetrics and Gynaecology (NVOG) developed and disse-
minated an evidence-based guideline about PPH, in which
the best scientific evidence is summarized [5]. Further-
more, in 2003 the MOET course (Managing Obstetric
Emergencies and Trauma), an ATLS-based course of the
RCOG, translated to the Dutch situation, was introduced,
in which stepwise and practical instructions to prevent
PPH were given [6]. However, without tailor-made imple-
mentation, in general large gaps exist between best evi-
dence as described in guidelines and daily practice [7,8].
This also applies to PPH. Both the dissemination of the
evidence-based guideline about PPH and the MOET
course did not lead to a reduction in PPH: nationwide the
incidence of PPH was 3.8% in 2003 and 5.2% in 2006 [3].
An incomplete implementation of both the NVOG-guide-
line and the MOET-instructions is expected.
Methods/Design
Objectives
The first objective of this study is to asses to what
extent the NVOG guidelines and the MOET-instruc-
tions have been implemented in current care in the
Dutch practice. The second objective is to study bar-
riers and facilitators for guideline adherence. Finally
based on these findings a tailored implementation
strategy will be developed and tested on effects, experi-
ences and costs.
Design and study population described per step
Objective 1
To assess the actual care of Dutch gynaecologists and
midwives for patients at high risk for PPH (actual care
study).
Design
Developing quality indicators
Before actual care can be measured, quality indicators
have to be developed regarding the process, structure
and outcome of care. These indicators have to be based
on the key recommendations from the NVOG guideline
on PPH and the MOET-instructions. The indicator
development will be performed according to the RAND-
modified Delphi method [9]. First the key recommenda-
tions from the NVOG guideline on PPH and the
MOET-instructions will be extracted and relevant indi-
cators from international literature will be added. Subse-
quently, the relevance of all these key recommendations
will be tested in two rounds among an independent
panel about 15 experts consisting of guideline writers,
Dutch MOET board members and instructors, NVOG-
members of the subcommittee Implementation and
Quality, gynaecologists, haematologist and anaesthesiol-
ogist. In the first round the gathered recommendations
will be edited in a written questionnaires for the expert
panel where the experts are asked to score the key-
recommendations on a 9-point Likert scale ranging
from 1 = not relevant to 9 = extremely relevant, with
respect to their impact on both ‘health gain’ and ‘overall
efficacy. In addition, a top-5 ranking of recommenda-
tions is asked in which they consider ‘most important’
and ‘representative’ to assess the quality of clinical per-
formance. In this round the experts have the possibility
to provide comments and add additional items as well.
Of the returned questionnaires, the median scores on
‘health gain’ and ‘overall efficacy’ are calculated per
recommendation and are rated valid if they match the
criteria described by Campbell [10]. Secondly, based on
the top-5 ranking of recommendations, a list with scores
reflecting the weight that experts assigned to each
recommendation will be created. In a second round, in
a consensus meeting with all the experts these listings
will be used as feedback. During this meeting this feed-
back will be discussed and the former rankings will be
reconsidered with the aim to reach consensus about the
most important recommendations to assess the quality
of clinical performance regarding the adherence to the
NVOG guideline on PPH and the MOET-instructions.
The selected key recommendations will be operationa-
lized in measurable elements.
The practical measurement of actual care
In an observational multi-centre study, actual care will
be measured by video monitoring the third stage of
delivery and a medical record search among 320 high
risk patients for PPH in 20 hospitals. In all participating
clinics, all delivery rooms will be set up with a digital
camera. In order to avoid anxiety, bias or refusal of par-
ticipation among the care-givers, it is made clear that
none of the direct colleagues or patients will be able to
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see the images and that these images cannot be claimed
by the patient in case of an adverse outcome. The
images will be analyzed by the researcher and in a ran-
dom selected subset by one of the project leaders to
assess the extent of adherence to the developed quality
indicators. Additional information for indicator adher-
ence will be searched in the medical records of the
videotaped patients. In this manner, deviations from the
indicators can be outlined. This study will provide us
with reliable information about current practice in the
Netherlands.
Study population
Hospitals
In order to obtain a representative view on the actual
care in the Netherlands, 20 hospitals of different regions
will participate in this trial including 4 academical, 8
non academical teaching and 8 non academical-non
teaching hospitals. The study is set in a Dutch Perinatal
Research Consortium, in which all the participating
clinics collaborate.
Patients
All patients 18 years and older with a higher risk for
PPH who will deliver in one of the participating hospi-
tals can be included (16 patients per hospital). This will
include women with PPH in a previous delivery, multi-
ple pregnancy, polyhydramnion, chorio-amnionitis,
uterus myomatosus, grande multiparity, long delivery,
clotting disorders or thrombocytopenia (HELLP). Since
asking permission during the delivery is difficult and the
higher risk of PPH can develop during delivery, all
women who visit the antenatal clinic will be asked in
advance by research nurses to participate. Informed con-
sent will be asked for filming the third stage of labour
and for reviewing these images by a third party; the
researcher. The group who declines will be asked per-
mission to study their medical record. In this way,
besides the total incidence of PPH in the study period,
the incidence of PPH in women who participate and
those who do not participate can be recorded
Objective 2
To detect barriers and facilitators amongst professionals
involved in the implementation of the NVOG-guideline
on PPH and the MOET-instructions and patients (bar-
riers and facilitators study).
Design
A qualitative study will be performed with the aim to
discover factors in detail that are “pro” or “contra”
adhering to the developed PPH-indicators. This will be
performed by focus group interviews among groups of
different involved professionals (gynaecologists, mid-
wives and gynaecologists in training) and experienced
patients. The interviewer will explore the following cate-
gories of influencing factors: features of the guidelines
itself; features of the target group of professionals who
should use the recommendations; features of patients
who have to accept or contribute to using the recom-
mendations; features of the social setting and social net-
work (e.g. colleagues of the involved professionals);
features of the organizational, economic, and adminis-
trative context. Subsequently, to assess the ‘prevalence’
of the factors mentioned in the focus group interviews,
a survey with questionnaires will be performed among
all Dutch gynaecologists and midwives. They will receive
a web-based questionnaire by e-mail. The data will be
gathered in an electronic database.
Study population
To select the members of the focus groups, we will con-
tact the national professional associations of respectively
gynaecologists and midwives and request nominations
for opinion leaders and the professionals participating in
the actual care study. The different focus groups will
consist of respectively 10 gynaecologists, 10 midwives,
10 gynaecologists in training and 10 patients. To select
the participants for the survey with questionnaires, we
will contact the national professional associations of
respectively gynaecologists and midwives and request e-
mail addresses.
Objective 3
Development and testing an implementation strategy in
terms of effectiveness, experiences of participants, pro-
cess and costs. (feasibility study):
Design
Based on the results of step 1 and 2, a tailored imple-
mentation strategy will be developed to increase the
adherence to the recommendations. Because different
barriers at different levels are expected, it is very likely
that a strategy with different implementation elements
directed at both professional and organizational level
will be developed. At this moment, we have some
hypotheses about expecting limitations in actual care. At
the level of the guideline/MOET-instructions itself we
think that the guideline can be more specific; the
description of the desired care is not detailed enough.
The desired care can be described in a detailed and
structural manor by the development of “bundles”.
These bundles are defined as a group of interventions
related to a disease process that, when executed
together, results in better outcome than when imple-
mented individually. A second limitation could be a
delayed time interval between events and taken actions,
(right actions taken too slowly due to individual deci-
sions or organizational factors). The solution could also
be describing the desired care in bundles in the guide-
line and on organizational level an improvement process
can be undertaken if the exact problem can be identified
for example; multidisciplinary clear agreements. At the
level of the professionals, a lack of knowledge/insight in
own performance can be an impending factor. The
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installed monitors could be used to constant audit and
feedback their performance, both individual and in
review conferences and team training could be an inter-
vention. However, due to uncertainty of existing barriers
and facilitators the strategy can not be worked out in
detail now.
Intervention
The tailored improvement strategy will be implemented
and evaluated in a feasibility study in nine months. The
study will be performed in 4 hospitals (also participating
in the actual care study) and consists of three
evaluations:
a) To obtain an indication of the effect of the imple-
mentation strategy, the adherence to the developed indi-
cators will be measured before (= actual care study) and
after the introduction of the newly developed strategy,
using videotaping and a medical record search (see step
1b). For the after-measurement we will include about
100 patients.
b) A process evaluation will be performed to study the
experiences of the clinicians and patients with the chan-
ged care and also to study the extent by which clinicians
and eventually patients use the elements of the strate-
gies and their experiences (e.g. satisfaction and feasibil-
ity) with these elements. To achieve this, process
information will be gathered in a qualitative study in the
4 participating hospitals and individual interviews will
take place among the different involved gynaecologists,
midwives and patients.
c) A cost analysis of the tested implementation strat-
egy will take place. The perspective of this analysis will
be the health care perspective. The costs of the imple-
mentation strategy will be estimated by an Activity
Based Costing approach focusing on activities performed
to implement the NVOG-guideline on PPH and the
MOET-instructions, with the costs accumulated at the
activity level(s) of the health care implementation pro-
cesses. The costs of implementation of the guidelines
and consolidation consist of personnel and material
costs. The input of resources will be assessed by collect-
ing volumes of consumed resources and multiplying
these by the price of each resource unit. The prices of
each resource unit will be based on standard costs, mar-
ket prices or self-determined costs [11]. In the analysis,
the implementation costs will be related to the differ-
ence in percentage of patients treated according to the
guideline indicators in the situation before and after the
implementation of the NVOG-guideline on PPH and
the MOET-instructions
Study population
To study the feasibility, four hospitals and their respec-
tive gynaecologists and midwives will participate in two
different regions in the Netherlands. In each region, an
academic hospital and a non-academic hospital will
participate. The inclusion criteria and course of manage-
ment for the 100 patients in the ‘after-measurement’ will
be the same as in the actual care study. For the process
evaluation all gynaecologists and midwives of the
included patients are asked to participate.
Outcome measures
Actual care study
The primary outcome measure is the adherence to the
quality indicators (derived from the NVOG guideline on
PPH and the MOET-instructions). The secondary out-
come measure is outcome of care (e.g. the incidence of
PPH).
Barrier and facilitator study
The main outcome is the different types and frequency
of found barriers and facilitators for implementation of
the NVOG guideline and MOET-instructions regarding
gynaecologists, midwifes and patients.
Feasibility study
To get an indication of the effectiveness of the strategy
the primary outcome measure is the adherence to devel-
oped quality indicators. Other outcome measures are
the experiences of the participants (both professionals
and patients) with the elements of the strategy and with
the changed care. Also the cost of the tested strategy
will be measured.
Statistical issues
Sample size calculation actual care study and feasibility of
recruitment
Assuming accordance with the guidelines of 50%, with an
alpha of 0.05, a precision of the estimation of 0.075, 171
patients have to be included. However, taking clustering of
data within clinicians into account, this number has to be
multiplied by the design effect. With 5 patients per clini-
cian and an intraclustercorrelation of 0.20 this effect is 1.8.
So the minimum number of patients that have to be
included is 1.8 × 171 = 308 patients. In order to compen-
sate for lost to follow-up or incomplete data, 320 women
have to be included in 20 hospitals in 6-9 months.
Data analysis
Analysis of the actual care study
To analyse actual care, frequencies of adherence per
quality indicator will be calculated. Furthermore, the
variation in this care between the different hospitals will
be calculated.
Analysis of the barriers and facilitators
The barriers and facilitators mentioned in the focus
group interviews with professionals and patients will be
qualitatively analysed, using the qualitative software
package (Atlas). In the quantification of these barriers,
frequencies of found barriers and facilitators will be
calculated.
Analysis of the feasibility study
In the effectuation the proportion of patients that are
treated in accordance with the guidelines (analysed on
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the basis of the indicator set) before and after imple-
mentation of the guidelines will be established. Both
univariate and multivariate (multi-level) analyses are
performed to demonstrate the effect of the implementa-
tion strategy in increasing the proportion of patients
who are treated according to the guidelines. In addition,
for the process evaluation, frequencies are used to asses
the experiences of the professionals and patients to the
implementation programme elements. Analyses of the
costs of the implementation strategy will be conducted
by multiplying the volumes of consumed resources with
the price of each resource unit.
Ethical considerations
The study protocol has been presented to the Medical
Ethical Committee (CMO) of the region Arnhem and
Nijmegen (ABR no. NL25975.091.08). Ethical approval
was not necessary. The protocol is registered in the
ClinicalTrials.gov register (NCT00928863)
Discussion
This study addresses an important problem because
PPH is currently the major cause of severe maternal
morbidity in the Netherlands. Many different factors
determine the action that is taken in case of more than
average blood loss or once a real PPH sets in. Insight
into these factors is of great importance in order to
know what kind of activities should be developed to pre-
vent PPH by implementing the NVOG-guideline and
MOET-instructions. In literature, the following facilita-
tors and barriers are distinguished: features of the inno-
vations itself, of the target group of professionals who
should use the innovation, of patients who have to
accept or contribute to the innovation, of the social set-
ting and network and of the organisational, economic
and administrative context [12]. To our knowledge the
proposed study is the first study on barriers and the
development and testing of a tailored implementation
strategy for acute care situations in the obstetrics. A
randomized controlled study is the next step to measure
the effectiveness of the implementation of the obtained
strategy if the result of this study is that the strategy is
feasible in practice, can be implemented with low costs
and indicates to be effective. Ultimately, the generated
knowledge and understanding of the implementation
process can be used to implement guidelines in different
countries with similar problems and hopefully lead to a
worldwide reduction of the incidence of PPH
Abbreviations
HELLP: Haemolysis Elevated Liver enzymes Low platelets; RCOG: Royal
College Obstetric Gynaecology; ATLS: Advance Trauma Life Support.
Acknowledgements
This study is funded by Zon-MW grant. No. 80-82315-98-09003
Author details
1Department of Obstetrics and Gynaecology, Radboud University Nijmegen,
Nijmegen, the Netherlands. 2IQ Healthcare, Radboud University Nijmegen,
Nijmegen, the Netherlands. 3Department of Obstetrics, Leiden University
Medical Centre, Leiden, the Netherlands. 4Department of anaesthesiology,
University Hospital Maastricht, Maastricht, the Netherlands. 5Department of
Obstetrics and Gynaecology, VU Medical Centre, Amsterdam, the
Netherlands. 6Department of Obstetrics and Gynaecology, University Hospital
Maastricht, Maastricht, the Netherlands.
Authors’ contributions
HS and RH were involved in conception and design of the study. MW, HS
and RH drafted the manuscript. All authors mentioned in the manuscript are
member of the Fluxim study group. They participated in the design of the
study during several meetings. All authors edited the manuscript and read
and approved the final manuscript.
Competing interests
The authors declare that they have no competing interests.
Received: 29 June 2009
Accepted: 26 January 2010 Published: 26 January 2010
References
1. Revised 1990 estimates on maternal mortality: a new approach by WHO
and UNICEF. 1990, Ref Type: Data File.
2. Schuitemaker N, van RJ, Dekker G, van DP, van GH, Bennebroek GJ:
Confidential enquiry into maternal deaths in The Netherlands 1983-
1992. Eur J Obstet Gynecol Reprod Biol 1998, 79:57-62.
3. Dutch Perinatal Registration Data. The LVR AND PRN data 2006.
4. Zwart JJ, Richters JM, Ory F, de Vries JI, Bloemenkamp KW, van RJ: Severe
maternal morbidity during pregnancy, delivery and puerperium in the
Netherlands: a nationwide population-based study of 371,000
pregnancies. BJOG 2008, 115:842-850.
5. Guideline: Haemorrhagia Post Partum by the Dutch Society of Obstetrics
and Gynaecology (NVOG). 2005, Ref Type: Data File.
6. Massive Obstetric Haemorrhage. Managing Obstetric Emergency and
Trauma; The MOET Course Manual London: RCOG PressJohanson R, Cox C,
Grady K, Howell C 2003, 149-162.
7. Grol R, Grimshaw J: From best evidence to best practice: effective
implementation of change in patients’ care. Lancet 2003, 362:1225-1230.
8. Grol R, Wensing M: Improving patient care: the implementation of
change in clinical practice. Oxford, Elsevier 2005.
9. Mourad SM, Hermens RP, Nelen WL, Braat DD, Grol RP, Kremer JA:
Guideline-based development of quality indicators for subfertility care.
Hum Reprod 2007, 22:2665-2672.
10. Campbell SM, Cantrill JA, Roberts D: Prescribing indicators for UK general
practice: Delphi consultation study. BMJ 2000, 321:425-428.
11. Oostenbrink JB, Koopmanschap MA, Rutten FF: Standardisation of costs:
the Dutch Manual for Costing in economic evaluations.
Pharmacoeconomics 2002, 20:443-454.
12. Mc Millan T, Hyzy R: Bringing quality improvement into the intensive of
care unit. Crit Care 2007, 35(2 Suppl):S59-65.
Pre-publication history
The pre-publication history for this paper can be accessed here:http://www.
biomedcentral.com/1471-2393/10/5/prepub
doi:10.1186/1471-2393-10-5
Cite this article as: Woiski et al.: Haemorrhagia post partum; an
implementation study on the evidence-based guideline of the Dutch
Society of Obstetrics and Gynaecology (NVOG) and the MOET
(Managing Obstetric Emergencies and Trauma-course) instructions;
the Fluxim study. BMC Pregnancy and Childbirth 2010 10:5.
Woiski et al. BMC Pregnancy and Childbirth 2010, 10:5
http://www.biomedcentral.com/1471-2393/10/5
Page 5 of 5
